On November 28, Xiangxue Pharmaceutical announced that Guangdong Hengyi Medical Co.
, Ltd.
, a subsidiary of the company, signed the "Project Transfer Agreement" with Xinyi Company and the guarantor Li Weijian, Liang Chengyu and Maoming Hengyi Investment Co.
, Ltd.
, to transfer 100% of the equity of its subsidiary Maoming Hengyi to Xinyi Company through equity transfer, with a total consideration of 180 million yuan: of which the equity transfer amount was 51.
36 million yuan, and Maoming Hengyi should borrow 129 million yuan from the shareholders paid by the parent company, Guangdong Hengyi Medical Co.
。
According to the announcement, after the completion of this transaction, Maoming Hengyi will no longer be included in the scope of accounting of Xiangxue Pharmaceutical's consolidated statements, and after preliminary calculations by the company's financial department, it is expected to increase the net profit in 2022 by about 5 million yuan, which will not have a significant impact
on the company's financial position and operating results.
Judging from the current market situation, in fact, the sale of assets by pharmaceutical companies has been happening
frequently in recent times.
For example, on November 21, ST Guodan issued an announcement that Jiangsu Guodan Biopharmaceutical Co.
, Ltd.
intends to sell part of its assets, API production workshop assets, to Jiangsu Yingke Biopharmaceutical Co.
, Ltd.
The company said that after the completion of this sale, it is conducive to optimizing the company's asset structure
.
In the long term, reducing fixed costs and finance expenses has a positive impact
on the company's future financial position.
Jingfeng Pharmaceutical said on November 17 that according to the needs of the company's business and strategic development, Shanghai Jingfeng, a wholly-owned subsidiary of the company, intends to sell its real estate located in Lane 868, Puming Road, Pudong New Area, Shanghai, with a total construction area of 701.
63 square meters, to Yue Hongwei, a natural person, for a transaction price of 120 million yuan
.
Regarding the sale of real estate, Jingfeng Pharmaceutical said that the sale is in line with the company's business development strategy plan, which is conducive to further improving management efficiency, reducing management costs, facilitating centralized management, and sustainable development of the company, and bringing positive impact
on the company's future financial status and operating results.
This time, on November 15, Harbour Biopharma also announced that it would sell the production plant of its Biomolecule R&D Innovation Center project to WuXi Hyde, a subsidiary of Biologics Biologics, for a transaction price of 146 million yuan
.
For the sale, Harbour Biologics said it aims to monetize assets under construction, reduce operating costs, reallocate property and other resources to drug development, invest in projects with growth prospects and more stable revenues, and establish a long-term strategic relationship
with WuXi Biologics.
It is worth noting that this is not the first time that Harbour Pharma has "broken arm" self-insurance
.
On November 11, Harbour Biopharma announced that it sold HCAb, a fully human heavy-chain antibody platform of its wholly-owned subsidiary Nona Biologics
, to Moderna in the United States.
In addition, last month, Harbour Pharmaceutical also issued two consecutive announcements, announcing that it had licensed its late-stage clinical bartolimab (FcRn monomab) to Enbipu Pharmaceutical Co.
, Ltd.
, a subsidiary of CSPC Pharmaceutical Group; At the same time, it ended its phase III clinical trial of tenacercept (HBM9036) in China and no new subjects
were enrolled.
.
.
.
.
.
.
In general, the experience of pharmaceutical companies similar to the above has continued to play out
in the industry.
At present, with the continuous deepening of medical reform and the sudden increase in cash pressure on enterprises, in addition to selling assets and stopping pipelines, some companies are also easing the pressure
through financing and layoffs.
The industry believes that in the future, in order to further promote the development of more valuable product pipelines, similar "dramas" are expected to continue to be staged
in the pharmaceutical circle.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
